S&P 500   5,061.82
DOW   37,735.11
QQQ   431.06
5 Small-Cap Energy Stocks Surged in Price and Volume on Friday
Novo Nordisk Arms Wegovy to Be a Triple Threat
Vital Farms Rides the Pasture-Raised Egg Trend to the Bank
3 Energy Plays for Cash Flow: Buy 1 or Buy Them All
M&T Bank, Goldman Sachs rise; Salesforce, Tesla fall, Monday, 4/15/2024
When Will the Next Bull Market Be?
Global smartphone shipments climb nearly 8% in 1st quarter as Samsung retakes the lead
S&P 500   5,061.82
DOW   37,735.11
QQQ   431.06
5 Small-Cap Energy Stocks Surged in Price and Volume on Friday
Novo Nordisk Arms Wegovy to Be a Triple Threat
Vital Farms Rides the Pasture-Raised Egg Trend to the Bank
3 Energy Plays for Cash Flow: Buy 1 or Buy Them All
M&T Bank, Goldman Sachs rise; Salesforce, Tesla fall, Monday, 4/15/2024
When Will the Next Bull Market Be?
Global smartphone shipments climb nearly 8% in 1st quarter as Samsung retakes the lead
S&P 500   5,061.82
DOW   37,735.11
QQQ   431.06
5 Small-Cap Energy Stocks Surged in Price and Volume on Friday
Novo Nordisk Arms Wegovy to Be a Triple Threat
Vital Farms Rides the Pasture-Raised Egg Trend to the Bank
3 Energy Plays for Cash Flow: Buy 1 or Buy Them All
M&T Bank, Goldman Sachs rise; Salesforce, Tesla fall, Monday, 4/15/2024
When Will the Next Bull Market Be?
Global smartphone shipments climb nearly 8% in 1st quarter as Samsung retakes the lead
S&P 500   5,061.82
DOW   37,735.11
QQQ   431.06
5 Small-Cap Energy Stocks Surged in Price and Volume on Friday
Novo Nordisk Arms Wegovy to Be a Triple Threat
Vital Farms Rides the Pasture-Raised Egg Trend to the Bank
3 Energy Plays for Cash Flow: Buy 1 or Buy Them All
M&T Bank, Goldman Sachs rise; Salesforce, Tesla fall, Monday, 4/15/2024
When Will the Next Bull Market Be?
Global smartphone shipments climb nearly 8% in 1st quarter as Samsung retakes the lead

Compare Stocks

Comparative Price Performance Over Time

Compare Stocks - Price & Volume

CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Bio-Rad Laboratories, Inc. stock logo
BIO
Bio-Rad Laboratories
$300.41
0.0%
$333.00
$261.59
$489.36
$8.57B0.87199,128 shs167,913 shs
Hologic, Inc. stock logo
HOLX
Hologic
$77.54
+0.3%
$75.64
$64.02
$87.88
$18.20B11.82 million shs1.61 million shs
STERIS plc stock logo
STE
STERIS
$201.26
-1.3%
$226.02
$180.54
$254.00
$19.89B0.79446,509 shs847,866 shs
Teva Pharmaceutical Industries Limited stock logo
TEVA
Teva Pharmaceutical Industries
$13.23
-0.5%
$13.41
$7.09
$14.47
$14.83B1.0510.80 million shs13.51 million shs
10 "Recession Proof" Stocks That Will Thrive in Any Market Cover

Which stocks are likely to thrive in today's challenging market? Click the link below and we'll send you MarketBeat's list of ten stocks that will drive in any economic environment.

Get This Free Report

Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Bio-Rad Laboratories, Inc. stock logo
BIO
Bio-Rad Laboratories
0.00%-7.44%-9.91%-5.68%-37.31%
Hologic, Inc. stock logo
HOLX
Hologic
0.00%-0.83%+1.87%+6.30%-8.09%
STERIS plc stock logo
STE
STERIS
0.00%-4.44%-11.32%-8.68%+9.37%
Teva Pharmaceutical Industries Limited stock logo
TEVA
Teva Pharmaceutical Industries
0.00%-6.67%-1.00%+17.49%+60.43%

MarketRank™

CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & Valuation
Bio-Rad Laboratories, Inc. stock logo
BIO
Bio-Rad Laboratories
4.6864 of 5 stars
3.44.00.04.21.93.31.9
Hologic, Inc. stock logo
HOLX
Hologic
4.6977 of 5 stars
3.24.00.04.22.02.52.5
STERIS plc stock logo
STE
STERIS
4.4335 of 5 stars
2.32.04.23.82.01.72.5
Teva Pharmaceutical Industries Limited stock logo
TEVA
Teva Pharmaceutical Industries
1.356 of 5 stars
2.43.00.00.02.01.71.3

Analyst Ratings

CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
Bio-Rad Laboratories, Inc. stock logo
BIO
Bio-Rad Laboratories
2.80
Moderate Buy$468.0055.79% Upside
Hologic, Inc. stock logo
HOLX
Hologic
2.44
Hold$87.0012.20% Upside
STERIS plc stock logo
STE
STERIS
2.50
Moderate Buy$239.6019.05% Upside
Teva Pharmaceutical Industries Limited stock logo
TEVA
Teva Pharmaceutical Industries
2.70
Moderate Buy$13.784.14% Upside

Current Analyst Ratings

Latest HOLX, STE, BIO, and TEVA Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
4/12/2024
STERIS plc stock logo
STE
STERIS
Needham & Company LLC
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingHold
4/10/2024
Hologic, Inc. stock logo
HOLX
Hologic
Needham & Company LLC
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Buy$90.00
4/4/2024
Hologic, Inc. stock logo
HOLX
Hologic
Evercore ISI
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost Price TargetIn-Line ➝ In-Line$76.00 ➝ $78.00
4/3/2024
Bio-Rad Laboratories, Inc. stock logo
BIO
Bio-Rad Laboratories
Citigroup
Subscribe to MarketBeat All Access for the recommendation accuracy rating
DowngradeBuy ➝ Neutral$400.00 ➝ $365.00
4/3/2024
Hologic, Inc. stock logo
HOLX
Hologic
Citigroup
Subscribe to MarketBeat All Access for the recommendation accuracy rating
UpgradeNeutral ➝ Buy$80.00 ➝ $95.00
3/8/2024
Teva Pharmaceutical Industries Limited stock logo
TEVA
Teva Pharmaceutical Industries
JPMorgan Chase & Co.
Subscribe to MarketBeat All Access for the recommendation accuracy rating
UpgradeUnderweight ➝ Neutral$14.00
2/16/2024
Bio-Rad Laboratories, Inc. stock logo
BIO
Bio-Rad Laboratories
UBS Group
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost Price TargetBuy ➝ Buy$395.00 ➝ $420.00
2/16/2024
Bio-Rad Laboratories, Inc. stock logo
BIO
Bio-Rad Laboratories
Royal Bank of Canada
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetOutperform ➝ Outperform$484.00 ➝ $480.00
2/12/2024
Teva Pharmaceutical Industries Limited stock logo
TEVA
Teva Pharmaceutical Industries
Piper Sandler
Subscribe to MarketBeat All Access for the recommendation accuracy rating
UpgradeNeutral ➝ Overweight$12.00 ➝ $19.00
2/9/2024
STERIS plc stock logo
STE
STERIS
Stephens
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingOverweight ➝ Overweight$250.00
2/8/2024
STERIS plc stock logo
STE
STERIS
JMP Securities
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingMarket Outperform ➝ Market Outperform$265.00
(Data available from 4/15/2021 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Sales & Book Value

CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
Bio-Rad Laboratories, Inc. stock logo
BIO
Bio-Rad Laboratories
$2.67B3.21$12.10 per share24.82$306.51 per share0.98
Hologic, Inc. stock logo
HOLX
Hologic
$4.03B4.52$5.35 per share14.49$20.48 per share3.79
STERIS plc stock logo
STE
STERIS
$4.96B4.01$18.62 per share10.81$61.31 per share3.28
Teva Pharmaceutical Industries Limited stock logo
TEVA
Teva Pharmaceutical Industries
$15.85B0.94$3.50 per share3.78$7.25 per share1.82

Profitability & Earnings

CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
Bio-Rad Laboratories, Inc. stock logo
BIO
Bio-Rad Laboratories
-$637.32M-$21.49N/A25.81N/A-23.86%3.90%2.77%5/2/2024 (Estimated)
Hologic, Inc. stock logo
HOLX
Hologic
$456M$2.1136.7517.742.6212.98%18.91%10.47%5/2/2024 (Confirmed)
STERIS plc stock logo
STE
STERIS
$107.03M$5.7135.2521.14N/A10.48%13.67%7.68%5/8/2024 (Estimated)
Teva Pharmaceutical Industries Limited stock logo
TEVA
Teva Pharmaceutical Industries
-$559M-$0.47N/A5.271.54-3.33%34.90%6.48%5/8/2024 (Confirmed)

Latest HOLX, STE, BIO, and TEVA Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
5/8/2024N/A
Teva Pharmaceutical Industries Limited stock logo
TEVA
Teva Pharmaceutical Industries
$0.49N/A-$0.49N/AN/AN/A  
5/2/2024N/A
Hologic, Inc. stock logo
HOLX
Hologic
$0.98N/A-$0.98N/AN/AN/A  
2/15/2024Q4 2023
Bio-Rad Laboratories, Inc. stock logo
BIO
Bio-Rad Laboratories
$2.93$3.10+$0.17-$5.94$685.00 million$681.18 million      
2/7/2024Q3 24
STERIS plc stock logo
STE
STERIS
$2.17$2.22+$0.05$3.02$1.35 billion$1.40 billion    
2/1/2024Q1 24
Hologic, Inc. stock logo
HOLX
Hologic
$0.95$0.98+$0.03$0.93$989.32 million$1.01 billion      
1/31/2024Q4 2023
Teva Pharmaceutical Industries Limited stock logo
TEVA
Teva Pharmaceutical Industries
$0.73$0.98+$0.25$1.55$3.97 billion$4.46 billion

Dividends

CompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive Growth
Bio-Rad Laboratories, Inc. stock logo
BIO
Bio-Rad Laboratories
N/AN/AN/AN/AN/A
Hologic, Inc. stock logo
HOLX
Hologic
N/AN/AN/AN/AN/A
STERIS plc stock logo
STE
STERIS
$2.081.03%+8.74%36.43%19 Years
Teva Pharmaceutical Industries Limited stock logo
TEVA
Teva Pharmaceutical Industries
N/AN/AN/AN/AN/A

Latest HOLX, STE, BIO, and TEVA Dividends

AnnouncementCompanyPeriodAmountYieldEx-Dividend DateRecord DatePayable Date
1/30/2024
STERIS plc stock logo
STE
STERIS
Quarterly$0.520.95%2/22/20242/23/20243/22/2024
(Data available from 1/1/2013 forward)

Debt

CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
Bio-Rad Laboratories, Inc. stock logo
BIO
Bio-Rad Laboratories
0.14
5.83
4.34
Hologic, Inc. stock logo
HOLX
Hologic
0.55
3.89
3.18
STERIS plc stock logo
STE
STERIS
0.50
2.43
1.49
Teva Pharmaceutical Industries Limited stock logo
TEVA
Teva Pharmaceutical Industries
2.23
1.02
0.69

Ownership

Institutional Ownership

CompanyInstitutional Ownership
Bio-Rad Laboratories, Inc. stock logo
BIO
Bio-Rad Laboratories
65.24%
Hologic, Inc. stock logo
HOLX
Hologic
94.73%
STERIS plc stock logo
STE
STERIS
94.69%
Teva Pharmaceutical Industries Limited stock logo
TEVA
Teva Pharmaceutical Industries
54.05%

Insider Ownership

CompanyInsider Ownership
Bio-Rad Laboratories, Inc. stock logo
BIO
Bio-Rad Laboratories
17.50%
Hologic, Inc. stock logo
HOLX
Hologic
1.75%
STERIS plc stock logo
STE
STERIS
0.95%
Teva Pharmaceutical Industries Limited stock logo
TEVA
Teva Pharmaceutical Industries
0.62%

Miscellaneous

CompanyEmployeesShares OutstandingFree FloatOptionable
Bio-Rad Laboratories, Inc. stock logo
BIO
Bio-Rad Laboratories
8,03028.52 million23.53 millionOptionable
Hologic, Inc. stock logo
HOLX
Hologic
6,990234.73 million230.62 millionOptionable
STERIS plc stock logo
STE
STERIS
17,10098.81 million97.88 millionOptionable
Teva Pharmaceutical Industries Limited stock logo
TEVA
Teva Pharmaceutical Industries
37,8511.12 billion1.11 billionOptionable

HOLX, STE, BIO, and TEVA Headlines

SourceHeadline
Harel Insurance Investments & Financial Services Ltd. Has $297.89 Million Holdings in Teva Pharmaceutical Industries Limited (NYSE:TEVA)Harel Insurance Investments & Financial Services Ltd. Has $297.89 Million Holdings in Teva Pharmaceutical Industries Limited (NYSE:TEVA)
marketbeat.com - April 14 at 1:28 PM
Teva Pharmaceutical Industries (NYSE:TEVA) Trading Down 5.3%Teva Pharmaceutical Industries (NYSE:TEVA) Trading Down 5.3%
americanbankingnews.com - April 14 at 4:42 AM
Teva Pharmaceutical Industries Limited (NYSE:TEVA) Receives Average Recommendation of "Moderate Buy" from AnalystsTeva Pharmaceutical Industries Limited (NYSE:TEVA) Receives Average Recommendation of "Moderate Buy" from Analysts
americanbankingnews.com - April 13 at 4:52 AM
Teva announces phase 3 study of Ajovy for prevention of migraine achieves primary and all secondary endpointsTeva announces phase 3 study of Ajovy for prevention of migraine achieves primary and all secondary endpoints
pharmabiz.com - April 13 at 1:45 AM
Teva Pharmaceutical Industries (NYSE:TEVA)  Shares Down 5.3% Teva Pharmaceutical Industries (NYSE:TEVA) Shares Down 5.3%
marketbeat.com - April 12 at 2:51 PM
Meitav Investment House Ltd. Acquires 1,950,500 Shares of Teva Pharmaceutical Industries Limited (NYSE:TEVA)Meitav Investment House Ltd. Acquires 1,950,500 Shares of Teva Pharmaceutical Industries Limited (NYSE:TEVA)
marketbeat.com - April 12 at 12:48 AM
Pfizer unit to settle Effexor XR antitrust claims in $39M dealPfizer unit to settle Effexor XR antitrust claims in $39M deal
msn.com - April 11 at 1:28 PM
Teva Confirms Efficacy, Safety Of AJOVY In Prevention Of Migraine - Quick FactsTeva Confirms Efficacy, Safety Of AJOVY In Prevention Of Migraine - Quick Facts
markets.businessinsider.com - April 11 at 1:28 PM
Teva Confirms Efficacy and Safety of AJOVY® (fremanezumab) for the Prevention of Migraine With Results from Phase 3 Trial in ChinaTeva Confirms Efficacy and Safety of AJOVY® (fremanezumab) for the Prevention of Migraine With Results from Phase 3 Trial in China
businesswire.com - April 11 at 8:30 AM
Stock Traders Buy High Volume of Teva Pharmaceutical Industries Call Options (NYSE:TEVA)Stock Traders Buy High Volume of Teva Pharmaceutical Industries Call Options (NYSE:TEVA)
americanbankingnews.com - April 10 at 1:16 AM
Teva to Host Conference Call to Discuss First Quarter 2024 Financial Results at 8 a.m. ET on May 8, 2024Teva to Host Conference Call to Discuss First Quarter 2024 Financial Results at 8 a.m. ET on May 8, 2024
businesswire.com - April 9 at 4:30 PM
Teva Pharmaceutical Industries Sees Unusually Large Options Volume (NYSE:TEVA)Teva Pharmaceutical Industries Sees Unusually Large Options Volume (NYSE:TEVA)
marketbeat.com - April 9 at 2:46 PM
Teva, mAbxience ink global licensing agreement for oncology biosimilar candidateTeva, mAbxience ink global licensing agreement for oncology biosimilar candidate
drugstorenews.com - April 9 at 12:37 PM
Teva Pharmaceutical Industries (NYSE:TEVA) Hits New 1-Year High at $14.47Teva Pharmaceutical Industries (NYSE:TEVA) Hits New 1-Year High at $14.47
marketbeat.com - April 8 at 1:45 PM
New Pharmacokinetic Modeling Data Presented by Teva Simulates Clinical Profiles of Schizophrenia Patients Switching to UZEDY® (risperidone) Extended-Release Injectable Suspension at SIRS 2024New Pharmacokinetic Modeling Data Presented by Teva Simulates Clinical Profiles of Schizophrenia Patients Switching to UZEDY® (risperidone) Extended-Release Injectable Suspension at SIRS 2024
finance.yahoo.com - April 6 at 1:13 PM
New Pharmacokinetic Modeling Data Presented by Teva Simulates Clinical Profiles of Schizophrenia Patients Switching to UZEDY® (risperidone) Extended-Release Injectable Suspension at SIRS 2024New Pharmacokinetic Modeling Data Presented by Teva Simulates Clinical Profiles of Schizophrenia Patients Switching to UZEDY® (risperidone) Extended-Release Injectable Suspension at SIRS 2024
businesswire.com - April 6 at 1:00 PM
Teva, mAbxience enter strategic global licensing agreement for oncology biosimilar candidateTeva, mAbxience enter strategic global licensing agreement for oncology biosimilar candidate
pharmabiz.com - April 6 at 2:08 AM
Teva links up with mAbxience on oncology biosimilar candidateTeva links up with mAbxience on oncology biosimilar candidate
thepharmaletter.com - April 5 at 9:56 AM
Teva and mAbxience Announce Strategic Global Licensing Agreement for Oncology Biosimilar CandidateTeva and mAbxience Announce Strategic Global Licensing Agreement for Oncology Biosimilar Candidate
finance.yahoo.com - April 4 at 8:52 AM
Biden touts inhaler price drops with Bernie Sanders: "Finally, finally we beat big Pharma"Biden touts inhaler price drops with Bernie Sanders: "Finally, finally we beat big Pharma"
msn.com - April 3 at 5:49 PM
The Interplay: Key Decisions at the Intersection of Antitrust & Life Sciences - March 2024The Interplay: Key Decisions at the Intersection of Antitrust & Life Sciences - March 2024
jdsupra.com - April 2 at 4:45 PM
Teva puts a face on tardive dyskinesia in latest Austedo XR spotsTeva puts a face on tardive dyskinesia in latest Austedo XR spots
mmm-online.com - April 1 at 1:56 PM
Teva, Viatris win new chance to challenge J&J schizophrenia drug patentTeva, Viatris win new chance to challenge J&J schizophrenia drug patent
reuters.com - April 1 at 11:53 AM
Clinical Collaboration Agreement between Teva and Launch Therapeutics to Accelerate Development of Dual-Action Asthma Rescue Inhaler (ICS-SABA/TEV-’248) Respiratory Program; Teva and Abingworth Enter Strategic Development Funding AgreementClinical Collaboration Agreement between Teva and Launch Therapeutics to Accelerate Development of Dual-Action Asthma Rescue Inhaler (ICS-SABA/TEV-’248) Respiratory Program; Teva and Abingworth Enter Strategic Development Funding Agreement
finance.yahoo.com - April 1 at 8:56 AM

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

All Headlines

Company Descriptions

Bio-Rad Laboratories logo

Bio-Rad Laboratories

NYSE:BIO
Bio-Rad Laboratories, Inc. manufactures and distributes life science research and clinical diagnostic products in the United States, Europe, Asia, Canada, and Latin America. It operates through two segments, Life Science and Clinical Diagnostics. The company develops, manufactures, and markets instruments, systems, reagents, and consumables to separate, purify, characterize, and quantitate biological materials such as cells, proteins, and nucleic acids for proteomics, genomics, biopharmaceutical production, cellular biology, and food safety markets. It also designs, manufactures, markets, and supports test systems, informatics systems, test kits, and specialized quality controls for hospitals, diagnostic reference, transfusion, and physician office laboratories. The company offers its products through its direct sales force, as well as through distributors, agents, brokers, and resellers. Bio-Rad Laboratories, Inc. was founded in 1952 and is headquartered in Hercules, California.
Hologic logo

Hologic

NASDAQ:HOLX
Hologic, Inc. develops, manufactures, and supplies diagnostics products, medical imaging systems, and surgical products for women's health through early detection and treatment. The company operates through four segments: Diagnostics, Breast Health, GYN Surgical, and Skeletal Health. It provides Aptima molecular diagnostic assays to detect the infectious microorganisms; Aptima viral load assays for Hepatitis B virus, Hepatitis C virus, human immunodeficiency virus, and human cytomegalo virus; Aptima bacterial vaginosis and candida vaginitis assays for the diagnosis of vaginitis; Aptima SARS-CoV-2 and Panther Fusion SARS-CoV-2 assays to detect SARS-CoV-2; ThinPrep System for cytology applications; and Rapid Fetal Fibronectin Test that assists physicians in assessing the risk of pre-term birth. The company also offers breast cancer care solutions in the areas of radiology, breast surgery, pathology, and treatment, such as 3D digital mammography systems, image analytics software, reading workstations, minimally invasive breast biopsy guidance systems, breast biopsy site markers, localization, specimen radiology, and connectivity solutions; and breast conserving surgery products. In addition, it provides MyoSure Hysteroscopic Tissue Removal System for the removal of fibroids and polyps in the uterus; NovaSure Endometrial Ablation System to treat abnormal uterine bleeding; Fluent Fluid Management System that provides liquid distention during diagnostic and operative hysteroscopic procedures; Acessa ProVu system to treat various fibroids; and CoolSeal portfolio, such as bipolar vessel sealing devices. Further, the company offers Horizon DXA, a dual energy X-ray system; and Fluoroscan Insight FD mini C-arm to perform minimally invasive orthopedic surgical procedures. It sells its products through direct sales, service forces, independent distributors, and sales representatives. Hologic, Inc. was incorporated in 1985 and is headquartered in Marlborough, Massachusetts.
STERIS logo

STERIS

NYSE:STE
STERIS plc provides infection prevention products and services worldwide. It operates through four segments: Healthcare, Applied Sterilization Technologies, Life Sciences, and Dental. The Healthcare segment offers cleaning chemistries and sterility assurance products; automated endoscope reprocessing system and tracking products; endoscopy accessories, washers, sterilizers, and other pieces of capital equipment for the operation of a sterile processing department; and equipment used directly in the operating room, including surgical tables, lights, and connectivity solutions, as well as equipment management services. It also provides capital equipment installation, maintenance, upgradation, repair, and troubleshooting services; preventive maintenance programs and repair services; instrument and endoscope repair and maintenance services; and custom process improvement consulting and outsourced instrument sterile processing services. The Applied Sterilization Technologies segment provides contract sterilization and testing services for medical device and pharmaceutical manufacturers through a network of approximately 50 contract sterilization and laboratory facilities. The Life Sciences segment designs, manufactures and sells consumable products, such as formulated cleaning chemistries, barrier, sterility assurance products, steam and vaporized hydrogen peroxide sterilizers, and washer disinfectors. This segment also offers equipment installation, maintenance, upgradation, repair, and troubleshooting services; and preventive maintenance programs and repair services. The Dental segment provides hand and electric-powered dental instruments, infection control products, conscious sedation, personal protective equipment, and water quality products for dental suite. The company serves its products and services to hospitals, other healthcare providers, and pharmaceutical manufacturers. The company was founded in 1985 and is based in Dublin, Ireland.
Teva Pharmaceutical Industries logo

Teva Pharmaceutical Industries

NYSE:TEVA
Teva Pharmaceutical Industries Limited develops, manufactures, markets, and distributes generic medicines, specialty medicines, and biopharmaceutical products in North America, Europe, Israel, and internationally. It offers generic medicines in various dosage forms, such as tablets, capsules, injectables, inhalants, liquids, transdermal patches, ointments, and creams; sterile products, hormones, high-potency drugs, and cytotoxic substances in parenteral and solid dosage forms; and generic products with medical devices and combination products. The company focuses on the central nervous system (CNS), respiratory, and oncology areas. It provides active pharmaceutical ingredients, as well as contract manufacturing services; and operates an out-licensing platform that offers a portfolio of products to other pharmaceutical companies. The company also offers BENDEKA and TREANDA injections for the treatment of chronic lymphocytic leukemia and indolent b-cell non-hodgkin's lymphoma; GRANIX; TRISENOX; LONQUEX; and TEVAGRASTIM/RATIOGRASTIM. In addition, it provides COPAXONE for the treatment of relapsing forms of multiple sclerosis; AJOVY for the preventive treatment of migraine in adults; AUSTEDO for the treatment of neurodegenerative and movement disorders associated with Huntington's disease and tardive dyskinesia; UZEDY for the treatment of schizophrenia; ProAir RespiClick inhalation powder; QVAR for treatment for asthma; BRALTUS, a long-acting muscarinic antagonist; CINQAIR/CINQAERO injection; DuoResp Spiromax, an inhaled corticosteroid and long-acting beta-agonist bronchodilator; and AirDuo RespiClick fluticasone propionate and salmeterol inhalation powder. The company offers its OTC products under SUDOCREM, NasenDuo, DICLOX FORTE, OLFEN Max, and FLEGAMINA brand names. It has collaboration agreements with MedinCell; Sanofi; Alvotech; and Biolojic Design Ltd., as well as license agreement with MODAG GmbH. The company was founded in 1901 and is based in Tel Aviv, Israel.